Interview with Federico Asch, M.D., FACC, FASE, associate director of the echocardiography core lab at Medstar Health Research Institute and assistant professor of medicine (cardiology) at Georgetown University, at the American Society of Echocardiography (ASE) 2016 annual meeting. Asch discusses the technology used for cardio-oncology cardiotoxcity assessments and how to set up these types of collaborative programs between oncology and cardiology. For more information, read the article Assessing Cardiotoxicity Due to Cancer Therapy.
News | Heart Failure| October 20, 2017
Trial Data Show Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
News | Cardiovascular Ultrasound| October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
Videos | Cardiovascular Ultrasound| October 12, 2017
Sharon Mulvagh, M.D., FRCPC, FACC, FAHA, FASE, professor, Division of Cardiology, Department of Medicine, Dalhouse Un
News | Clinical Decision Support| October 11, 2017
Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR Appropriateness...